Cancer and Oncology Research

Prof. A.R. Thierry has a strong background in synthetic DNA complex formation, notably its use for the in vivo gene therapy he developed for cancer and HIV at the Georgetown University and the US National Cancer Institute, with Dr RC Gallo. He was the principal founder of MedinCell SA (Jacou, France) devoted initially to the development of drug delivery system, in particular for nucleic acids. His area of expertise is particularly applicable to research which focusses on the diagnostic capacity of circulating nucleic acids (cirDNA), and on the development of methods which support personalized medicine. His team has developed an modèle préclinique model to specifically quantify the different origins of cirDNA, and has demonstrated the importance of short cirDNA fragment detection for high specificity and sensitivity in cirDNA analysis.That observation enabled dominant IP and the design of the IntPlex test. At the Inst. Cancer Res. of Montpellier (INSERM), France, A.R. Thierry coordinated the first prospective blinded multicenter study to offer clinical validation of plasma analysis which detects mutations in cancer patients. Recently, his team was the first to demonstrate the clinical utility of using cirDNA analysis for mCRC patients

DNA complex formation,ivo gene therapy he developed for cancer and HIV

Professor Dooley has a distinguished career in clinical and translational research into breast cancer at Johns Hopkins where he was the founding director of the Johns Hopkins Breast Center and now as the G. Rainey Williams Chair of Surgical Breast Oncology at the University of Oklahoma Stepheson Cancer Center NCI CC. He has won national and international awards for his efforts which include a lifetime achievement award for his work in the intraductal approach to breast cancer. He and Dr. Mukherjee are now developing the next generation of submillimeter endoscopy devices and tools to allow liquid biopsy through such tiny endoscopes.

Surgical Oncology, Breast Cancer, Sarcoma, Melanoma, Pseudomyxoma Peritonei

Benny Abraham Kaipparettu major research interest of Dr. Kaipparettu is in breast cancer stem cells (His publications before 2006 was with the name Abraham BK due to official name change). After bachelor and master degree in pharmacy, Dr. Kaipparettu continued his career in pharmacogenomics and obtained PhD in Pharmacology for his research in CYP2D6 polymorphism. During his first postdoctoral fellowship in Germany, Dr. Kaipparettu focused on pharmacogenomics in breast cancer. In 2003 when initial reports about putative breast cancer stem cells (BCSCs) published, he investigated its clinical significance in breast tumors and published one of the first studies on the clinical significance of BCSCs. His observations suggested the relevance of BCSCs in distant metastasis. The findings in his publication were further verified by several other research groups and extensively cited in other cancer stem cell publications. Later he moved to Baylor College of Medicine, Houston, USA and continued his work on the regulation of cancer stem cell markers by hormone receptors and its epigenetic silencing. In 2009 Dr Kaipparettu was promoted as a Junior Faculty in Baylor College of Medicine and in 2010 he has became an Assistant Professor in the Department of Molecular and Human Genetics, Baylor College of Medicine.

Tumour initiating cells, Mitochondrial Nuclear Cross talk in Cancer, Cancer epigenetics, Pharmacogenomics, Epigenetics and energy regulation in breast tumor initiating cells.